For adults with persistent acne, spironolactone has direct trial support, metformin fits acne with polycystic ovary syndrome, and bicalutamide is an off-label specialist option. Persistent acne means facial acne that lasts into adulthood despite routine care. This briefing compares what each option showed, who it fits, and what safety checks apply.
Spironolactone was tested against placebo in adult women and earned a conditional guideline role. Metformin improved acne severity in women with polycystic ovary syndrome by lowering androgen-driven oil production. Bicalutamide blocks androgen receptors but carries strict pregnancy and liver warnings.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How strong is the case for spironolactone?
- When does metformin help acne?
- Where does bicalutamide fit?
- What safety checks shape the decision?
How strong is the case for spironolactone?
In the SAFA phase 3 double-blind trial, 410 adult women with persistent facial acne received spironolactone or placebo. The University of Southampton/NIHR team reported significantly greater acne improvement and quality-of-life gains at 12 and 24 weeks, described in the full BMJ trial report. Gains were recorded at both time points.
The American Academy of Dermatology's 2024 acne guidelines give oral spironolactone a conditional recommendation. Choice depends on severity, tolerance, preferences, and physician judgment. That framing supports case-by-case use rather than automatic use.
When does metformin help acne?
In women with polycystic ovary syndrome, metformin treatment significantly reduced acne severity, with p less than 0.001. The J Clin Aesthet Dermatol review attributed the change to reduced ovarian hyperandrogenism and lower androgen-driven sebum production, detailed in the clinic review on PMC. Sebum is the oily secretion that can clog pores.
That result does not make metformin a general acne drug. It fits best when polycystic ovary syndrome drives excess androgens and oily skin. Medical review still decides whether acne, cycle changes, or metabolic signs point that way.
Where does bicalutamide fit?
Bicalutamide is a nonsteroidal androgen-receptor blocker approved for prostate cancer. A 2021 Dermatology Times review of antiandrogens reports low-dose off-label use for acne and other polycystic ovary syndrome signs. The same review describes it as better tolerated than flutamide.
Its limits are strict. The FDA bicalutamide label contraindicates use in women who are or may become pregnant because it may cause fetal harm, as stated in the FDA bicalutamide label. The label also requires liver transaminase monitoring because severe liver injury typically occurs in the first three to four months.
What safety checks shape the decision?
All three paths need pregnancy avoidance and medical supervision. Gloucestershire Hospitals NHS patient information notes spironolactone takes several months for visible effect and needs potassium review in at-risk adults.
Bicalutamide needs contraception plus liver-function monitoring. Bring a full drug list, potassium risks, pregnancy plans, and liver history to the prescribing visit.
- Spironolactone: the FDA label warns about hyperkalemia, bars use with hyperkalemia or Addison's disease, and directs serum potassium checks within one week and regularly after, per the FDA spironolactone label.
- Metformin: the FDA label carries a boxed warning for rare lactic acidosis that can cause death, with hypothermia, low blood pressure, and resistant slow heart rhythm.
- Warning signs listed for lactic acidosis include malaise, muscle pain, and breathing distress.
- Bicalutamide: use requires no pregnancy risk and planned liver blood tests during early months.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: A Source-Checked 2026 Briefing for Adults With Persistent Acne